Skip to main content

Peer Review reports

From: Bortezomib administration is a risk factor associated with the development of tumor lysis syndrome in male patients with multiple myeloma: a retrospective study

Original Submission
10 Apr 2020 Submitted Original manuscript
23 Jul 2020 Author responded Author comments - Masahiro Kondo
2 May 2020 Reviewed Reviewer Report
30 May 2020 Reviewed Reviewer Report
5 Jun 2020 Reviewed Reviewer Report
Resubmission - Version 2
23 Jul 2020 Submitted Manuscript version 2
23 Sep 2020 Author responded Author comments - Masahiro Kondo
16 Aug 2020 Reviewed Reviewer Report
5 Aug 2020 Reviewed Reviewer Report
Resubmission - Version 3
23 Sep 2020 Submitted Manuscript version 3
24 Oct 2020 Author responded Author comments - Masahiro Kondo
9 Oct 2020 Reviewed Reviewer Report
Resubmission - Version 4
24 Oct 2020 Submitted Manuscript version 4
28 Oct 2020 Author responded Author comments - Masahiro Kondo
Resubmission - Version 5
28 Oct 2020 Submitted Manuscript version 5
Publishing
29 Oct 2020 Editorially accepted
17 Nov 2020 Article published 10.1186/s12885-020-07592-9

You can find further information about peer review here.

Back to article page
\